NDLI: Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Please wait, while we are loading the content...

Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation

Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia

Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products

Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies

Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles

Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer

Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development

Engineered Mannitol Ternary Additives Improve Dispersion of Lactose–Salbutamol Sulphate Dry Powder Inhalations

Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice

Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity

Assessment of Juvenile Pigs to Serve as Human Pediatric Surrogates for Preclinical Formulation Pharmacokinetic Testing

Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients

Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition

Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies

What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data

Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Non-Arrhenius Protein Aggregation

Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists

Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment

Epigenetic Modifications of Nrf2 by 3,3′-diindolylmethane In Vitro in TRAMP C1 Cell Line and In Vivo TRAMP Prostate Tumors

Bioequivalence for Locally Acting Nasal Spray and Nasal Aerosol Products: Standard Development and Generic Approval

Utilization of Gene Expression Signature for Quality Control of Traditional Chinese Medicine Formula Si-Wu-Tang

Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics

Year: 2013, Volume: 15, Issue: 2

Year: 2013, Volume: 15, Issue: 1

Year: 2012, Volume: 15

Year: 2012, Volume: 14

Year: 2011, Volume: 14

Year: 2011, Volume: 13

Year: 2010, Volume: 13

Year: 2010, Volume: 12

Year: 2009, Volume: 12

Year: 2009, Volume: 11

Year: 2008, Volume: 10

Year: 2007, Volume: 9

Year: 2006, Volume: 8

Year: 2005, Volume: 7

Year: 2004, Volume: 6

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Content Provider	PubMed Central
Author	Bonate, Peter L. Suttle, Ben
Abstract	Tumor growth profiles were simulated for 2 years using the Wang and Claret models under a phase 3 clinical trial design. Profiles were censored when tumor size increased >20% from nadir similar to clinical practice. The percent of patients censored varied from 0% (perfect case) to 100% (real-life case). The model used to generate the data was then fit to the censored data using FOCE in NONMEM. The percent bias in the estimated model parameters determined with censored data was compared to the true values. A total of 100 simulation replicates was used. For the Wang model, under clinical conditions (100% censoring), the parameter related to tumor reduction SR was underpredicted by 30% and the parameter related to tumor growth PR was underpredicted by ∼45%. Most of the variance components in the model were within ±20% of the true values. However, biased parameter estimates in the Wang model did not translate to biased tumor size predictions as the mean percent prediction error between true and model predicted tumor size never exceeded 10%. For the Claret model, at 100% censoring, the tumor growth parameter KL was unaffected by censoring. Both tumor shrinkage parameters, KD and λ, were overestimated by ∼20% in both cases. Future research needs to be directed to develop less empirically based models and to use simulation as a way to improve clinical oncology trials designs.
Related Links	http://dx.doi.org/10.1208/s12248-013-9487-1
Ending Page	839
Page Count	8
Starting Page	832
File Format	PDF
ISSN	15507416
e-ISSN	15507416
Journal	The AAPS Journal
Issue Number	3
Volume Number	15
Language	English
Publisher	Springer US
Publisher Date	2013-07-01
Access Restriction	Open
Rights Holder	Springer US
Subject Keyword	Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Population Pharmacodynamic Parameter Estimation from Sparse Sampling: Effect of Sigmoidicity on Parameter Estimates

Parameter estimations for mixed generalized exponential distribution based on progressive type-I interval censoring

Exact Likelihood Inference for an Exponential Parameter under Generalized Adaptive Progressive Hybrid Censoring

Bias Due to Left Truncation and Left Censoring in Longitudinal Studies of Developmental and Disease Processes

Parameter Estimation Based on Censored Data under Partially Accelerated Life Testing for Hybrid Systems due to Unknown Failure Causes

Pharmacodynamic parameter estimation: Population size versus number of samples

On Progressive Censoring

The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Similar Documents

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

Population Pharmacodynamic Parameter Estimation from Sparse Sampling: Effect of Sigmoidicity on Parameter Estimates

Parameter estimations for mixed generalized exponential distribution based on progressive type-I interval censoring

Exact Likelihood Inference for an Exponential Parameter under Generalized Adaptive Progressive Hybrid Censoring

Bias Due to Left Truncation and Left Censoring in Longitudinal Studies of Developmental and Disease Processes

Parameter Estimation Based on Censored Data under Partially Accelerated Life Testing for Hybrid Systems due to Unknown Failure Causes

Pharmacodynamic parameter estimation: Population size versus number of samples

On Progressive Censoring

The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates